| scholarly article | Q13442814 |
| P50 | author | Scott Kopetz | Q51789838 |
| Jaffer Ajani | Q64913003 | ||
| Sunil Krishnan | Q89944934 | ||
| Dipen Maru | Q91302122 | ||
| Wayne L. Hofstetter | Q107450763 | ||
| Sushovan Guha | Q114453617 | ||
| Zhimin Tong | Q114453640 | ||
| Omkara Veeranki | Q114453641 | ||
| P2093 | author name string | Steven Lin | |
| Defeng Deng | |||
| Alicia Mejia | |||
| Devkumar Chatterjee | |||
| P2860 | cites work | CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression. | Q36962507 |
| Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases | Q37333518 | ||
| Barrett's esophagus: diagnostic challenges and recent developments | Q37477732 | ||
| Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers | Q37536656 | ||
| Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer | Q37636710 | ||
| Targeting cyclin-dependent kinases in anti-neoplastic therapy | Q38135008 | ||
| Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis | Q38332838 | ||
| EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer | Q38392935 | ||
| Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. | Q39577806 | ||
| Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation | Q39895438 | ||
| 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects | Q40216003 | ||
| Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials | Q44261463 | ||
| Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer | Q46487396 | ||
| The selective P-TEFb inhibitor CAN508 targets angiogenesis. | Q54572692 | ||
| Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States | Q82749733 | ||
| Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma | Q84522311 | ||
| The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508 | Q27676963 | ||
| Regulatory functions of Cdk9 and of cyclin T1 in HIV tat transactivation pathway gene expression | Q28146067 | ||
| Cdks, cyclins and CKIs: roles beyond cell cycle regulation | Q28294632 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Mcl-1 ubiquitination: unique regulation of an essential survival protein | Q33883844 | ||
| A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261 | Q34023223 | ||
| PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells | Q34140712 | ||
| CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma | Q34342934 | ||
| Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer | Q35037270 | ||
| Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction | Q35208151 | ||
| Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia | Q35550068 | ||
| Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia | Q35615823 | ||
| Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas | Q35681702 | ||
| Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. | Q35868187 | ||
| Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma | Q36547753 | ||
| Myeloid cell leukemia-1 (Mc1-1) is a candidate target gene of hypoxia-inducible factor-1 (HIF-1) in the testis | Q36565158 | ||
| Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. | Q36610386 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 28696-28710 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma | |
| P478 | volume | 8 |
| Q59797085 | Cyclin-dependent kinase 9 as a potential specific molecular target in NK cell leukemia/lymphoma |
| Q92434462 | Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma |
| Q92434912 | Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma |
Search more.